In addition, a recently published phase I study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumors, with an expansion in renal, endometrial, or bladder cancer confirmed the PD effect of sapanisertib on downstream effectors of TORC1 (p4EBP1 and pS6) and TORC2 (pPRAS40 and pNDRG1), with treatment-related decreases in p4EBP1, pS6, pPRAS40, and pNDRG1 using single-agent sapanisertib doses of ≥4 mg (17). This evidence concerns the gene CRTC1 and urinary bladder cancer.